JP2018535972A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018535972A5 JP2018535972A5 JP2018522651A JP2018522651A JP2018535972A5 JP 2018535972 A5 JP2018535972 A5 JP 2018535972A5 JP 2018522651 A JP2018522651 A JP 2018522651A JP 2018522651 A JP2018522651 A JP 2018522651A JP 2018535972 A5 JP2018535972 A5 JP 2018535972A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- naturally encoded
- encoded amino
- antibody
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical group 0.000 claims 32
- 230000001472 cytotoxic effect Effects 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 3
- 230000001588 bifunctional effect Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 229920003169 water-soluble polymer Polymers 0.000 claims 2
- JSXMFBNJRFXRCX-NSHDSACASA-N (2s)-2-amino-3-(4-prop-2-ynoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OCC#C)C=C1 JSXMFBNJRFXRCX-NSHDSACASA-N 0.000 claims 1
- NEMHIKRLROONTL-QMMMGPOBSA-N (2s)-2-azaniumyl-3-(4-azidophenyl)propanoate Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N=[N+]=[N-])C=C1 NEMHIKRLROONTL-QMMMGPOBSA-N 0.000 claims 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N Folic acid Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 229960000304 folic acid Drugs 0.000 claims 1
- 235000019152 folic acid Nutrition 0.000 claims 1
- 239000011724 folic acid Substances 0.000 claims 1
- 125000003929 folic acid group Chemical group 0.000 claims 1
- 125000003827 glycol group Chemical group 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 230000004481 post-translational protein modification Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021132397A JP7220755B2 (ja) | 2015-11-03 | 2021-08-16 | 新規な抗ｃｄ３抗体およびその使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562250451P | 2015-11-03 | 2015-11-03 | |
| US62/250,451 | 2015-11-03 | ||
| US201562267086P | 2015-12-14 | 2015-12-14 | |
| US62/267,086 | 2015-12-14 | ||
| US201662374693P | 2016-08-12 | 2016-08-12 | |
| US62/374,693 | 2016-08-12 | ||
| PCT/US2016/060087 WO2017079272A2 (en) | 2015-11-03 | 2016-11-02 | Anti-cd3-folate conjugates and their uses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021132397A Division JP7220755B2 (ja) | 2015-11-03 | 2021-08-16 | 新規な抗ｃｄ３抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018535972A JP2018535972A (ja) | 2018-12-06 |
| JP2018535972A5 true JP2018535972A5 (enExample) | 2019-12-12 |
| JP6931649B2 JP6931649B2 (ja) | 2021-09-08 |
Family
ID=58662682
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018522651A Active JP6931649B2 (ja) | 2015-11-03 | 2016-11-02 | 新規な抗ｃｄ３抗体およびその使用 |
| JP2021132397A Active JP7220755B2 (ja) | 2015-11-03 | 2021-08-16 | 新規な抗ｃｄ３抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021132397A Active JP7220755B2 (ja) | 2015-11-03 | 2021-08-16 | 新規な抗ｃｄ３抗体およびその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11851488B2 (enExample) |
| EP (1) | EP3370771A4 (enExample) |
| JP (2) | JP6931649B2 (enExample) |
| KR (1) | KR20180077271A (enExample) |
| CN (1) | CN108348603B (enExample) |
| AU (1) | AU2016349786C1 (enExample) |
| BR (1) | BR112018009004A8 (enExample) |
| CA (1) | CA3002573A1 (enExample) |
| IL (1) | IL258759B2 (enExample) |
| MX (1) | MX2018005232A (enExample) |
| NZ (1) | NZ743049A (enExample) |
| SG (2) | SG10201913746RA (enExample) |
| WO (1) | WO2017079272A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021503899A (ja) * | 2017-11-22 | 2021-02-15 | ジェルター， インコーポレイテッド | コラーゲンを操作するための方法およびシステム |
| KR20210063351A (ko) * | 2018-08-28 | 2021-06-01 | 암브룩스, 인코포레이티드 | 항-cd3 항체 폴레이트 생체접합체 및 이들의 용도 |
| KR102239781B1 (ko) * | 2019-04-08 | 2021-04-13 | 주식회사 녹십자 | Gpnmb 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도 |
| US20200392230A1 (en) * | 2019-05-14 | 2020-12-17 | Qlb Biotherapeutics | Bispecific anti-cd3 x cd20 antibodies and uses thereof |
| CN120775051A (zh) | 2019-05-21 | 2025-10-14 | 诺华股份有限公司 | Cd19结合分子及其用途 |
| TWI888487B (zh) * | 2020-02-14 | 2025-07-01 | 日商協和麒麟股份有限公司 | 與ｃｄ３結合之雙特異性抗體 |
| TWI827807B (zh) * | 2020-02-26 | 2024-01-01 | 香港商潤俊（中國）有限公司 | 抗cd3抗體葉酸生物共軛物及其用途 |
| WO2021173889A1 (en) | 2020-02-26 | 2021-09-02 | Ambrx, Inc. | Uses of anti-cd3 antibody folate bioconjugates |
| CN116157416A (zh) | 2020-08-25 | 2023-05-23 | 吉利德科学公司 | 靶向hiv的多特异性抗原结合分子及其使用方法 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| FR2504010B1 (fr) | 1981-04-15 | 1985-10-25 | Sanofi Sa | Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| DE3377484D1 (en) | 1982-04-19 | 1988-09-01 | Nissan Motor | Method for controlling reduction ratio of continuously variable transmission with acceleration compensation |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
| US4625014A (en) | 1984-07-10 | 1986-11-25 | Dana-Farber Cancer Institute, Inc. | Cell-delivery agent |
| US4542225A (en) | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
| US4659839A (en) | 1984-10-10 | 1987-04-21 | Mallinckrodt, Inc. | Coupling agents for radiolabeled antibody fragments |
| EP0188256B1 (en) | 1985-01-14 | 1991-08-21 | NeoRx | Metal radionuclide labeled proteins for diagnosis and therapy |
| US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
| US4699784A (en) | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
| US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| DK0615451T3 (da) | 1992-05-26 | 2006-04-24 | Immunex Corp | Hidtil ukendt cytokin der binder til CD30 |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| ES2297889T3 (es) | 1997-07-14 | 2008-05-01 | Bolder Biotechnology, Inc. | Derivados de hormona de crecimiento y proteinas relacionadas. |
| US6451986B1 (en) | 1998-06-22 | 2002-09-17 | Immunex Corporation | Site specific protein modification |
| CA2348822A1 (en) | 1998-10-30 | 2000-05-11 | Novozymes A/S | Glycosylated proteins having reduced allergenicity |
| CA2487424C (en) | 2002-05-30 | 2011-01-04 | The Scripps Research Institute | Copper-catalysed ligation of azides and acetylenes |
| EP1613735B1 (en) | 2003-04-17 | 2012-01-25 | The Scripps Research Institute | Expanding the eukaryotic genetic code |
| CN102618605B (zh) | 2003-06-18 | 2015-09-02 | 斯克利普斯研究院 | 非天然活性氨基酸遗传密码增加 |
| GB0716160D0 (en) | 2007-08-17 | 2007-09-26 | Biotransformations Ltd | Materials and methods for treating cancers which express folate receptors |
| JP2012034668A (ja) | 2010-08-12 | 2012-02-23 | Tohoku Univ | ヒト型化抗ｅｇｆｒ抗体リジン置換可変領域断片及びその利用 |
| JP6400470B2 (ja) * | 2011-05-16 | 2018-10-03 | ジェネロン（シャンハイ）コーポレイション リミテッド | 多重特異性Ｆａｂ融合タンパク質および使用法 |
| SMT201900239T1 (it) * | 2011-05-21 | 2019-05-10 | Macrogenics Inc | Molecole di legame a cd3 in grado di legare cd3 umano e non umano |
| US9718893B2 (en) * | 2011-12-19 | 2017-08-01 | Synimmune Gmbh | Bispecific antibody molecule |
| US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
| JP2016531100A (ja) | 2013-07-12 | 2016-10-06 | ザイムワークス，インコーポレイテッド | 二重特異的なｃｄ３及びｃｄ１９抗原結合構築物 |
| EP2840091A1 (en) * | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof |
| EP3172235A2 (en) * | 2014-07-25 | 2017-05-31 | Cytomx Therapeutics Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| JP2018534933A (ja) * | 2015-11-02 | 2018-11-29 | ヤンセン ファーマシューティカ エヌ．ベー． | 抗ｉｌ１ｒａｐ抗体、ｉｌ１ｒａｐとｃｄ３を結合する二重特異性抗原結合分子、及びその使用 |
| US20210179734A1 (en) * | 2018-04-17 | 2021-06-17 | Invenra Inc. | Trivalent trispecific antibody constructs |
| KR20210063351A (ko) * | 2018-08-28 | 2021-06-01 | 암브룩스, 인코포레이티드 | 항-cd3 항체 폴레이트 생체접합체 및 이들의 용도 |
| MX2021009644A (es) * | 2019-02-12 | 2021-09-08 | Ambrx Inc | Composiciones que contienen, metodos y usos de conjugados de anticuerpo-agonista de tlr. |
| CN116178547A (zh) * | 2019-02-22 | 2023-05-30 | 武汉友芝友生物制药股份有限公司 | Cd3抗原结合片段及其应用 |
-
2016
- 2016-11-02 BR BR112018009004A patent/BR112018009004A8/pt not_active Application Discontinuation
- 2016-11-02 IL IL258759A patent/IL258759B2/en unknown
- 2016-11-02 US US15/773,167 patent/US11851488B2/en active Active
- 2016-11-02 CN CN201680064414.8A patent/CN108348603B/zh active Active
- 2016-11-02 SG SG10201913746RA patent/SG10201913746RA/en unknown
- 2016-11-02 EP EP16862859.2A patent/EP3370771A4/en not_active Withdrawn
- 2016-11-02 SG SG11201803211TA patent/SG11201803211TA/en unknown
- 2016-11-02 NZ NZ743049A patent/NZ743049A/en unknown
- 2016-11-02 JP JP2018522651A patent/JP6931649B2/ja active Active
- 2016-11-02 AU AU2016349786A patent/AU2016349786C1/en active Active
- 2016-11-02 WO PCT/US2016/060087 patent/WO2017079272A2/en not_active Ceased
- 2016-11-02 KR KR1020187015756A patent/KR20180077271A/ko not_active Ceased
- 2016-11-02 MX MX2018005232A patent/MX2018005232A/es unknown
- 2016-11-02 CA CA3002573A patent/CA3002573A1/en active Pending
-
2021
- 2021-08-16 JP JP2021132397A patent/JP7220755B2/ja active Active
-
2023
- 2023-11-06 US US18/503,113 patent/US20240239889A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018535972A5 (enExample) | ||
| JP2019033743A5 (enExample) | ||
| US11833190B2 (en) | Serum albumin-binding fibronectin type III domains | |
| ES2916468T3 (es) | Nuevo formato biespecífico adecuado para su uso en el cribado de alto rendimiento | |
| HRP20211318T1 (hr) | Mutirani polipeptidi interleukina-2 | |
| ES2967739T3 (es) | Formato de anticuerpo heterodimérico multiespecífico dirigido al menos a CD3 y a HSA | |
| JP2017529067A5 (enExample) | ||
| JP2016536322A5 (enExample) | ||
| RU2016151265A (ru) | Антитела, направленные на cd127 | |
| ES2822431T3 (es) | Polipéptidos de unión a IL-17A | |
| JP2013506411A5 (enExample) | ||
| CN102906112A (zh) | Trail r2-特异性多聚体支架 | |
| RU2015100656A (ru) | Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения | |
| JP2010535032A5 (enExample) | ||
| JP2014505463A5 (enExample) | ||
| JP2011501951A5 (enExample) | ||
| RU2018141360A (ru) | Contorsbody - одноцепочечный связывающий мишень агент | |
| JP2017529870A5 (enExample) | ||
| JP2017523781A5 (enExample) | ||
| JP2008515889A5 (enExample) | ||
| JP2017534296A5 (enExample) | ||
| JP2019505565A5 (enExample) | ||
| Gerling-Driessen et al. | Exploiting Oligo (amido amine) backbones for the multivalent presentation of coiled-coil peptides | |
| RU2016107874A (ru) | Связывающие рецептор bag3 молекулы для применения в качестве лекарственного средства | |
| JP7014727B2 (ja) | ポリペプチドライブラリ |